IL-17A-derived from patients with SSc might be promising therapeutic targets for the treatment of SSc-related vasculopathy. PubMed, Arthritis Res Ther, 2014 Dec 31;16(6):4223. (Also see: Interleukin-17 and Scleroderma)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.